• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

No­vo Nordisk takes For­ma’s sick­le cell treat­ment in­to Phase 3

6 months ago
R&D

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

6 months ago
R&D
Pharma

J&J's Darza­lex hits pri­ma­ry end­point in Phase 3 ear­ly-stage mul­ti­ple myelo­ma tri­al

6 months ago
R&D

Gilead and Ar­cel­lx spot­light safe­ty of mul­ti­ple myelo­ma cell ther­a­py, dose first pa­tient in Phase 3

6 months ago
R&D
Cell/Gene Tx

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

6 months ago
R&D

Syn­dax inks a $350M roy­al­ty deal; FDA push­es back de­ci­sion on Organon’s eczema drug

6 months ago
News Briefing

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

6 months ago
R&D
Cell/Gene Tx

Prog­nomiQ rais­es $34M for lung can­cer test

6 months ago
Deals
Diagnostics

Up­dat­ed: Ver­tex makes mon­ey from gene-edit­ed ther­a­py Cas­gevy

6 months ago
Pharma

Nek­tar di­vests man­u­fac­tur­ing site and reagent arm for $90M 

6 months ago
Deals
Manufacturing

Why hos­pi­tals have been slow to adopt AI for med­ical care

6 months ago
Startups
AI

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

6 months ago
R&D

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

6 months ago
R&D
Manufacturing

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

6 months ago
Pharma
FDA+

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

6 months ago
Pharma
FDA+

Rare dis­ease bio­phar­ma com­pa­nies weigh in on FDA's new in­no­va­tion hub

6 months ago
FDA+

BioN­Tech eas­es 2024 rev­enue out­look de­spite hefty Covid vac­cine third-quar­ter sales

6 months ago
Pharma

FDA ex­pands faster drug re­view pi­lot from sup­ple­men­tal to full ap­pli­ca­tions

6 months ago
Pharma
FDA+

BioN­Tech says VEGF bis­pe­cif­ic’s PD-L1 tar­get, com­bo plans will be its edge

6 months ago
R&D
Pharma

No­vo, As­cendis to work on month­ly GLP-1; KalVista makes a roy­al­ty deal

6 months ago
News Briefing

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

6 months ago
R&D
Pharma

Is there room for MASH drugs in a GLP-1 world?

6 months ago
R&D
Pharma

Eu­ro­pean Com­mis­sion marks Dec. 6 for No­vo-Catal­ent deal de­ci­sion

6 months ago
Deals
Manufacturing

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

6 months ago
R&D
Pharma
First page Previous page 69707172737475 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.